TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study in Nature Communications found that imidazole propionate, a molecule made by some gut bacteria, was associated with Alzheimer’s-related biological markers and faster cognitive decline. Mouse experiments also linked the molecule to amyloid and tau accumulation, but the findings do not show that ImP causes Alzheimer’s in people or that lowering it prevents the disease.
Researchers at the University of Wisconsin-Madison report that imidazole propionate, a molecule produced by some gut bacteria, may be connected to Alzheimer’s-related brain changes. In mouse experiments, the compound was linked to increased amyloid and tau accumulation; among nearly 1,200 people studied, higher blood levels were associated with markers of abnormal proteins and faster cognitive decline. The findings point to a possible research target, but do not establish that the molecule causes Alzheimer’s disease in humans.
The study, published in Nature Communications, examined imidazole propionate, or ImP. Certain intestinal bacteria produce it while using histidine, an amino acid needed by the body. The researchers say ImP levels vary substantially between people, and bacteria that produce it can be present without being abundant.
In experiments with mice, ImP that reached the brain was associated with greater accumulation of abnormal beta-amyloid and tau proteins. These proteins are hallmarks associated with Alzheimer’s disease. The researchers described the results as evidence that ImP may contribute to brain changes, rather than proof that it causes the disease.
The team also analyzed blood samples from almost 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies through the Wisconsin Alzheimer’s Disease Research Center. Higher ImP concentrations were associated with biological markers linked to abnormal proteins and impaired neuron function. Participants with higher levels also showed faster cognitive decline over time on testing, according to the report.
The researchers identified a genetic variation associated with substantially higher ImP levels in blood; about 43% of participants carried it. They suspect the variation may affect how efficiently the kidneys clear ImP, but the proposed mechanism remains a hypothesis. The study also involved collaborators from the University of California, Los Angeles, and the University of Gothenburg.
A Possible Target Beyond Diet
The results add a specific molecule to research into how the gut and brain may be connected in dementia. If further work confirms that ImP contributes to disease-related changes, researchers could investigate whether reducing the molecule—or changing how it is produced or cleared—might help lower risk or slow decline. That possibility is relevant because it suggests a potential target distinct from the amyloid and tau processes already studied in Alzheimer’s research.
However, the human findings show an association, not cause and effect. People with higher ImP levels may differ in other ways that contribute to their cognitive outcomes. No treatment to lower ImP was tested, and the study does not show that changing ImP levels would prevent Alzheimer’s or improve symptoms. The proposed comparison to cholesterol-lowering drugs is a research possibility, not evidence that an equivalent intervention is available or effective.
The finding also does not support cutting out particular foods. Since gut bacteria produce ImP while processing histidine, and histidine is an essential amino acid found in many foods, the researchers say dietary reduction may not be simple or appropriate. The practical relevance for patients remains unknown.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
From Gut Microbes to ImP
The Wisconsin research builds on work by team leaders Barbara Bendlin and Federico Rey. Nearly a decade ago, their group reported differences in gut microorganism profiles between people with Alzheimer’s disease and healthy individuals. The later research aimed to explore how such differences might relate to changes in the brain.
ImP had previously been linked in research to type 2 diabetes and coronary artery disease. The new study extends investigation of the molecule to brain-related measures. According to Rey, ImP-producing bacteria occur in many people but are generally not very abundant; the researchers’ point is that a microbe need not be plentiful to affect its host.
The project received support in part from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture, according to the study report.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, University of Wisconsin-Madison professor of medicine, as quoted in the ScienceDaily report
Causation and Treatment Remain Open
The study does not establish that elevated ImP causes Alzheimer’s disease in people. The mouse experiments provide evidence of a possible biological effect, while the human analysis links blood concentrations with disease-related markers and cognitive change. Those findings cannot by themselves show that lowering ImP would change a person’s risk or progression.
It is also unclear what accounts for the differences in ImP levels across people. The researchers suspect the identified genetic variation may affect kidney clearance, but that explanation needs further testing. The report does not specify a level at which ImP would be considered harmful, how consistently levels change over time, or whether results apply across different populations.
No human trial of an ImP-lowering treatment was reported. Nor does the research establish a dietary plan for reducing the molecule. The amount of risk attributable to ImP, if any, and the number of people who might benefit from a targeted intervention remain unknown.
Testing Whether ImP Can Be Lowered
The next steps are to test how ImP affects brain processes, clarify the role of the genetic variation and kidney clearance, and determine whether the associations hold in additional groups of people. Researchers would also need to establish whether an intervention can safely and reliably lower ImP in the blood.
Only after those questions are addressed could clinical studies test whether reducing ImP changes Alzheimer’s-related biomarkers, cognitive decline or disease risk. For now, the work identifies a potential research target; it does not change established prevention or treatment guidance.
Key Questions
What is imidazole propionate?
Imidazole propionate (ImP) is a molecule produced by some gut bacteria as they use histidine, an amino acid needed by the body. It can enter the bloodstream, according to the researchers.
Does the study prove that ImP causes Alzheimer’s?
No. Mouse experiments linked ImP to increased amyloid and tau accumulation, and a human study found associations with disease-related markers and faster cognitive decline. These results do not prove causation in people.
Should people avoid foods containing histidine?
The report does not recommend avoiding histidine-rich foods. Histidine is essential and occurs in many foods; the researchers say reducing it through diet may not be a simple approach. The study did not test a dietary intervention.
Is there a treatment that lowers ImP?
The study did not report a tested ImP-lowering treatment. Researchers suggested that a future drug targeting the molecule could be investigated, but whether such an approach is safe or would affect Alzheimer’s risk or progression is unknown.
Source: rss
